PINELLAS PARK, Fla., MARCH 28, 2019 – Transitions Optical and Johnson & Johnson Vision today announced the U.S. availability of ACUVUE® OASYS with TRANSITIONS™ LIGHT INTELLIGENT TECHNOLOGY™ beginning April 1. The first-of-its-kind photochromic contact lens was named one of TIME’s ‘Best Inventions of 2018.’ The contact lenses seamlessly adapt to changing light , helping eyes recover from bright light up to five seconds faster, reducing halos and starbursts at night, and delivering more effortless sight with less squinting, from dawn to dusk. ,Ⅲ
"We have a long history of strategic partnerships that have enabled us to provide new light-adaptive technologies," said Chrystel Barranger, president of Essilor Photochromics and Transitions Optical. “Now we've re-invented our unique TRANSITIONS technology, formulated to specifically activate within ACUVUE Brand Contact Lenses, enabling a revolutionary contact lens experience that reduces the stressful impact that light can have on your eyes. This is in line with our passion to provide the best options for consumers to help protect their eyes both indoors and out.”
ACUVUE OASYS with TRANSITIONS have been developed in partnership between Johnson & Johnson Vision Care, Inc. and Transitions Optical Limited, combining the respective strengths of each organization. While Johnson & Johnson Vision is the world’s leader in contact lenses, Transitions Optical is the leading provider of photochromic (smart adaptive) eyeglass lenses worldwide. The two organizations are working together to research and deliver best-in-class vision care innovations.
ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY is a two-week reusable contact lens. It will be commercially available in U.S. beginning April 1. For more information or to find an eye care professional near you, visit www.acuvue.com/transitions. Follow the conversation at #SquintLessSeeMore.
This is one of two innovations for Transitions Optical this year; along with the upcoming launch of the next generation of TRANSITIONS® SIGNATURE® eyeglass lenses – TRANSITIONS® SIGNATURE® GEN 8™, which will be available in the U.S. in July. TRANSITIONS SIGNATURE GEN 8 lenses are engineered with new proprietary technology, that delivers the best overall photochromic eyeglass lens performance.
Lenses are not a replacement for sunglasses.
Important Information for Contact Lens Wearers: ACUVUE® Brand Contact Lenses are only available by prescription for vision correction as a daily wear lens with a two-week recommended replacement. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call 1-800-843-2020 or visit Acuvue.com.
†Helps protect against transmission of harmful UV radiation to the cornea and into the eye.
‡WARNING: UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. You should continue to use UV-absorbing eyewear as directed. NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. Consult your eye care practitioner for more information.
The third-party trademarks used herein are trademarks of their respective owners.
ACUVUE OASYS is a trademark of Johnson & Johnson Vision Care, Inc. 2018. Transitions is a registered trademark, and the Transitions logo, Transitions Light Intelligent Technology and Transitions Light Intelligent Lenses are trademarks of Transitions Optical, Inc. used under license by Transitions Optical Limited and Johnson and Johnson Vision Care, Inc.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding ACUVUE OASYS with Transitions. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Vision Care, Inc., any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of regulatory approvals; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Johnson & Johnson Vision Care, Inc., the Johnson & Johnson Medical Devices Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.